Reboxetine: a selective norepinephrine reuptake inhibitor for the treatment of depression (Q34093609)

31 July 2017

1 reference

title

Reboxetine: a selective norepinephrine reuptake inhibitor for the treatment of depression (English)

1 reference

31 July 2017

0 references

A C Scates

1

1 reference

31 July 2017

P M Doraiswamy

series ordinal

2

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 November 2000

1 reference

Annals of Pharmacotherapy

31 July 2017

published in

1 reference

31 July 2017

volume

34

1 reference

31 July 2017

issue

11

1 reference

31 July 2017

page(s)

1302-1312

1 reference

Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey

31 July 2017

cites work

1 reference

The role of corticotropin-releasing factor in depression and anxiety disorders

21 January 2018

1 reference

Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake

21 January 2018

1 reference

Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor

21 January 2018

1 reference

Is there a role for a pure noradrenergic drug in the treatment of depression?

21 January 2018

1 reference

Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein binding

21 January 2018

1 reference

Comparison of the disposition and of the metabolic pattern of Reboxetine, a new antidepressant, in the rat, dog, monkey and man.

21 January 2018

1 reference

Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive offsodes

21 January 2018

1 reference

21 January 2018

1 reference

Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder

21 January 2018

1 reference

Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale

21 January 2018

1 reference

Continuation drug therapy for major depressive episodes: how long should it be maintained?

21 January 2018

1 reference

Reboxetine in the maintenance therapy of depressive disorder in the elderly: a long-term open study.

21 January 2018

1 reference

The effects of reboxetine and amitriptyline, with and without alcohol on cognitive function and psychomotor performance

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.19335

1 reference

31 July 2017

1 reference